Found: 46
Select item for more details and to access through your institution.
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 6, p. 770, doi. 10.1111/jvh.13067
- By:
- Publication type:
- Article
Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 10, p. 1376, doi. 10.1177/0091270010387428
- By:
- Publication type:
- Article
Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 6, p. 943, doi. 10.1177/0091270010375959
- By:
- Publication type:
- Article
Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 3, p. 422, doi. 10.1177/0091270010367652
- By:
- Publication type:
- Article
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Lack of detectable HIV-1-specific CD8(+) T cell responses in Zambian HIV-1-exposed seronegative partners of HIV-1-positive individuals.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Lack of Detectable HIV-1-Specific CD8<sup>+</sup> T Cell Responses in Zambian HIV-1-Exposed Seronegative Partners of HIV-1-Positive Individuals.
- Published in:
- Journal of Infectious Diseases, 2011, v. 203, n. 2, p. 258, doi. 10.1093/infdis/jiq028
- By:
- Publication type:
- Article
Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 10, p. 1229, doi. 10.1111/jvh.13159
- By:
- Publication type:
- Article
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
- Published in:
- Clinical Infectious Diseases, 2021, v. 73, n. 2, p. e485, doi. 10.1093/cid/ciaa988
- By:
- Publication type:
- Article
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 6, p. 1379, doi. 10.1093/cid/ciz999
- By:
- Publication type:
- Article
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
- Published in:
- Clinical Infectious Diseases, 2019, v. 69, n. 3, p. 514, doi. 10.1093/cid/ciy913
- By:
- Publication type:
- Article
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.
- Published in:
- 2018
- By:
- Publication type:
- journal article
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S464, doi. 10.1093/ofid/ofz360.1151
- By:
- Publication type:
- Article
318. Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis of 7 Clinical Trials.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S168, doi. 10.1093/ofid/ofz360.391
- By:
- Publication type:
- Article
1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S64, doi. 10.1093/ofid/ofz359.139
- By:
- Publication type:
- Article
2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S864, doi. 10.1093/ofid/ofz360.2168
- By:
- Publication type:
- Article
Correction to: Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
- Published in:
- Clinical Drug Investigation, 2018, v. 38, n. 3, p. 239, doi. 10.1007/s40261-017-0606-0
- By:
- Publication type:
- Article
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2017, v. 16, n. 3, p. 375, doi. 10.5604/01.3001.0009.8592
- By:
- Publication type:
- Article
A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 6, p. 641, doi. 10.1002/cpdd.390
- By:
- Publication type:
- Article
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 312, n. 4, p. 353, doi. 10.1001/jama.2014.7734
- By:
- Publication type:
- Article
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
- Published in:
- Clinical Infectious Diseases, 2018, v. 67, n. 6, p. 934, doi. 10.1093/cid/ciy201
- By:
- Publication type:
- Article
Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.
- Published in:
- Clinical Infectious Diseases, 2017, v. 65, n. 5, p. 864, doi. 10.1093/cid/cix441
- By:
- Publication type:
- Article
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
- Published in:
- Clinical Infectious Diseases, 2017, v. 65, n. 1, p. 6, doi. 10.1093/cid/cix260
- By:
- Publication type:
- Article
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
- Published in:
- Clinical Infectious Diseases, 2017, v. 65, n. 1, p. 13, doi. 10.1093/cid/cix289
- By:
- Publication type:
- Article
Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
- Published in:
- 2017
- By:
- Publication type:
- Letter to the Editor
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
- Published in:
- Clinical Infectious Diseases, 2017, v. 64, n. 8, p. 1035, doi. 10.1093/cid/cix025
- By:
- Publication type:
- Article
Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
- Published in:
- Clinical Infectious Diseases, 2017, v. 64, n. 1, p. 44, doi. 10.1093/cid/ciw676
- By:
- Publication type:
- Article
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 11, p. 1479, doi. 10.1093/cid/ciw579
- By:
- Publication type:
- Article
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 11, p. 1405, doi. 10.1093/cid/ciw580
- By:
- Publication type:
- Article
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 9, p. 1202, doi. 10.1093/cid/ciw507
- By:
- Publication type:
- Article
Ledipasvir‐sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
- Published in:
- Liver International, 2018, v. 38, n. 9, p. 1552, doi. 10.1111/liv.13685
- By:
- Publication type:
- Article
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis.
- Published in:
- Liver International, 2018, v. 38, n. 3, p. 443, doi. 10.1111/liv.13534
- By:
- Publication type:
- Article
Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia.
- Published in:
- Liver International, 2018, v. 38, n. 3, p. 451, doi. 10.1111/liv.13540
- By:
- Publication type:
- Article
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.
- Published in:
- Liver International, 2016, v. 36, n. 8, p. 1101, doi. 10.1111/liv.13082
- By:
- Publication type:
- Article
Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with severe COVID-19 treated with remdesivir.
- Published in:
- Infection & Chemotherapy, 2020, v. 52, p. S384
- By:
- Publication type:
- Article
Racial/ethnic Disparities Not Observed in Clinical Outcomes with Remdesivir Treatment.
- Published in:
- Infection & Chemotherapy, 2020, v. 52, p. S382
- By:
- Publication type:
- Article
Association Between Concomitant Hydroxychloroquine Use and Safety and Efficacy of Remdesivir in Severe COVID-19 Patients.
- Published in:
- Infection & Chemotherapy, 2020, v. 52, p. S380
- By:
- Publication type:
- Article
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.
- Published in:
- Journal of Medical Virology, 2019, v. 91, n. 7, p. 1313, doi. 10.1002/jmv.25454
- By:
- Publication type:
- Article
Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
- Published in:
- 2018
- By:
- Publication type:
- journal article